+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Metabolomics Biomarker Market Research and Forecast 2018-2023

  • ID: 4602836
  • Report
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • Ab Sciex
  • Biomark Diagnostics Inc.
  • Creative Proteomics.
  • Merck Kgaa,
  • Metanomics Health Gmbh
  • Ovid Therapeutics Inc.
  • MORE
Metabolomics is referred as the large-scale study of small molecules, commonly known as metabolites, within tissues, cells, biofluids or organisms. Collectively, these small molecules and their interactions within a biological system are known as the metabolome. Metabolites have been used as biomarkers for decades. The oldest application of metabolomics involves identifying presence of sugar in urine for diabetes. Study of metabolites results in a growing number of biomarkers that is transforming the healthcare and life science industry. Metabolomics is a powerful tool as the metabolites and their concentrations reflects the primary biochemical activity and state of tissues/cells.

Innovative development in informatics and analytical technologies and increasing pharmaceutical and biotech R&D expenditure are expected to significantly contribute in the market growth during forecast period. Other factors such as ongoing research on metabolomics biomarker and extensive application of metabolomics biomarker such as in colorectal cancer detection are also expected to drive the market growth. Further, increasing pharmaceutical and biotech R&D expenditure is also contributing in the market. Limitations in biological and experimental measurements, high capital cost of tools and instruments and limited well-qualified researchers are limiting the growth of the market. However, increasing demand of drug development and personalized medicine and huge investments in metabolomics biomarker research is creating enormous opportunities for the market.

The global metabolomics biomarker is segmented on the basis of application, technology and end user. On the basis of application, the market is segmented into toxicological studies, drug testing, cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism and other. There is huge scope for the market in cancer segment due to increasing application of metabolomics biomarker in detection of colorectal cancer across the globe. Further, on the basis of technology, the market is segmented into gas chromatography, high-performance liquid chromatography, ultra-performance liquid chromatography, nuclear magnetic resonance, mass spectrometry, surface-based mass analysis, bioinformatics, and other. On the basis of end user, the market is segmented into hospitals, diagnostic labs and research centres. Research centres holds the largest market share in the market due to the presence of large number of research institute focused on discovery of innovative biomarkers across the globe.

Furthermore, the global Metabolomics Biomarker market is classified on the basis of geographical regions, including North America, Europe, Asia Pacific & RoW. North America leads the global metabolomics biomarkers market during forecast. The growth of the North American market is attributed to the increasing funding support for biomarkers discovery and development and growing usage of biomarkers in drug discovery & development within the region. Furthermore, APAC is expected to witness the highest growth rate in the global metabolomics biomarker market owing to the increasing prevalence of colorectal cancer within the regional countries. Further, developing countries such as China and India are the key region that have attributed extensively towards the growth of the Metabolomics biomarkers market in APAC market.

Some of the key vendors of the global Metabolomics biomarker consists Biocrates Life Sciences Ag, Biomark Diagnostics Inc., Chenomx Inc., Creative Proteomics, Evotec A.G., Human Metabolome Technologies America, Inc., Merck KGaA, Metabolomic Diagnostics Ltd., Metabolon, Inc., and Ovid Therapeutics Inc. These companies adopt various strategies such as mergers & acquisitions and partnership to be competitive in the aerospace & defense industry. For instance, in 2016, Ovid Therapeutics and NeuroPointDX collaborated to identify biomarkers for angelman syndrome by analyzing metabolomic profile data.

Research Methodology

The market study of Global Metabolomics Biomarker market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

Financial reports of companies involved in the market
Authentic Public Databases such as hmdb.ca, Canadian Institutes of Health Research Metabolomics Innovation Centre (TMIC) and so on.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue

The report is intended for research institutes, hospitals, government and pharmaceuticals companies for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers and initial norms. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

Global Metabolomics Biomarker Market is segmented on the basis of regional outlook and following segments:

Global Metabolomics Biomarker Market Research and Analysis, By End-users
Global Metabolomics Biomarker Market Research and Analysis, By Application
Global Metabolomics Biomarker Market Research and Analysis, By Technology
Global Metabolomics Biomarker Market Research and Analysis, By Region

The Report covers:

Comprehensive research methodology of global metabolomics biomarker market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global metabolomics biomarker market.
Insights about market determinants which are stimulating the global metabolomics biomarker market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ab Sciex
  • Biomark Diagnostics Inc.
  • Creative Proteomics.
  • Merck Kgaa,
  • Metanomics Health Gmbh
  • Ovid Therapeutics Inc.
  • MORE
Chapter 1. Report Summary
1.1. Research Methods And Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

Chapter 2. Market Overview And Insights
2.1. Market Definition
2.2. Parent Market Analysis: Global Biomarker Market
2.3. Analyst Insight & Current Market Trends
2.3.1. Key Findings
2.3.2. Recommendation
2.3.3. Conclusion
2.4. Rules & Regulations
2.4.1.1. United States
2.4.1.2. European Union
2.4.1.3. China
2.4.1.4. Japan
2.4.1.5. India

Chapter 3. Market Determinant
3.1. Motivators
3.1.1. Innovative Developments In Informatics And Analytical Technologies
3.1.2. Ongoing Research On Metabolomics Biomarker
3.1.3. Potential Advantages In Sensitivity And Specificity
3.1.4. Extensive Application Of Metabolomics Biomarker Such As In Colorectal Cancer Detection
3.1.5. Increasing Pharmaceutical And Biotech R&D Expenditure
3.2. Restraints
3.2.1. Limitations In Biological And Experimental Measurements
3.2.2. High Capital Cost Of Tools And Instruments
3.2.3. Limited Well-Qualified Researchers
3.3. Opportunities
3.3.1. Increasing Demand Of Drug Development And Personalized Medicine
3.3.2. Huge Investments In Metabolomics Biomarker Research

Chapter 4. Market Segmentation
4.1. Global Metabolomics Biomarker Market, By Application
4.1.1. Toxicological Studies
4.1.2. Drug Testing
4.1.3. Cancer
4.1.4. Cardiovascular Disorders
4.1.5. Neurological Disorders
4.1.6. Inborn Errors Of Metabolism
4.1.7. Other
4.2. Global Metabolomics Biomarker Market, By Technologies
4.2.1. Gas Chroma
4.2.2. Tography (Gc)
4.2.3. High-Performance Liquid Chromatography (Hplc)
4.2.4. Ultra-Performance Liquid Chromatography (Uplc)
4.2.5. Nuclear Magnetic Resonance (Nmr)
4.2.6. Mass Spectrometry
4.2.7. Surface Based Mass Analysis
4.2.8. Bioinformatics
4.2.9. Other
4.3. Global Metabolomics Biomarker By End Users
4.3.1. Hospitals
4.3.2. Diagnostic Labs
4.3.3. Research Centres

Chapter 5. Competitive Landscape
5.1. Key Company Analysis
5.2. Key Strategy Analysis

Chapter 6. Regional Analysis
6.1. North American
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. U.K
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Roe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Roapac
6.4. Rest Of The World

Chapter 7. Company Profiles
7.1. Ab Sciex
7.2. Bg Medicine Inc.
7.3. Biocrates Life Sciences Ag
7.4. Biomark Diagnostics Inc.
7.5. Chenomx Inc.
7.6. Creative Proteomics.
7.7. Evotec A.G.
7.8. Human Metabolome Technologies America, Inc.
7.9. Merck Kgaa,
7.10. Metabolomic Diagnostics Ltd.
7.11. Metabolon, Inc.
7.12. Metanomics Health Gmbh
7.13. Nightingale Health
7.14. Ovid Therapeutics Inc.
7.15. Owl Metabolomics
7.16. Prosciento, Inc.
7.17. Sidmap Llc
7.18. Stemina Biomarker Discovery, Inc.
7.19. System Biosciences, Llc.
7.20. Thermofisher Scientific Inc.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ab Sciex
  • Bg Medicine Inc.
  • Biocrates Life Sciences Ag
  • Biomark Diagnostics Inc.
  • Chenomx Inc.
  • Creative Proteomics.
  • Evotec A.G.
  • Human Metabolome Technologies America, Inc.
  • Merck Kgaa,
  • Metabolomic Diagnostics Ltd.
  • Metabolon, Inc.
  • Metanomics Health Gmbh
  • Nightingale Health
  • Ovid Therapeutics Inc.
  • Owl Metabolomics
  • Prosciento, Inc.
  • Sidmap Llc
  • Stemina Biomarker Discovery, Inc.
  • System Biosciences, Llc.
  • Thermofisher Scientific Inc.
Note: Product cover images may vary from those shown
Adroll
adroll